TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39253357

Group type: EXPERIMENTAL
Intervention: ChAd63-KH vaccine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 39253360

Group type: EXPERIMENTAL
Intervention: EEG-triggered rTMS of the ipsilesional M1 (1,200 pulses; 0.33 Hz; 100% RMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-frequency rTMS of the contralesional motor cortex (1,200 pulses; 1 Hz; 115% RMT)
Number of subjects: 30
Study: 39253712

Group type: EXPERIMENTAL
Intervention: hs-cTnT >9.6 ng/L (highest category)
Number of subjects: 708
Study: 39253713

Group type: EXPERIMENTAL
Intervention: RAS inhibitors prescribed in patients with periprocedural myocardial injury (197 patients, 70%)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: RAS inhibitors prescribed in patients without periprocedural myocardial injury (1,251 patients, 71.2%)
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Patients without periprocedural myocardial injury
Number of subjects: 2083
Study: 39253804

Group type: EXPERIMENTAL
Intervention: Toxocara canis infection (positive serology)
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: IgE concentration and eosinophil count
Number of subjects: 986
Study: 39253832

Group type: EXPERIMENTAL
Intervention: Virtual Yoga Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39254129

Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, single treatment of 30 minutes at peak negative pressure of 4.5 to 8 MPa.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, after optimal therapy settings determined.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, effectiveness in lower pole stones.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, effectiveness in distal ureteral stones.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, safety outcomes.
Number of subjects: 44
Study: 39254220

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Decreased cortical cerebral blood flow (CBF)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Increased amyloid burden
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: MTL CBF and amyloid
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Lower regional gray matter CBF
Number of subjects: 661
Study: 39254446

Group type: EXPERIMENTAL
Intervention: nnU-Net model for lesion segmentation and categorization using classic radiomics and autoencoder features
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Histopathologically or follow-up-confirmed diagnosis
Number of subjects: 1241
Study: 39254458

Group type: EXPERIMENTAL
Intervention: US shear-wave elastography (SWE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 0
Study: 39254466

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy for 24 hours per day
Number of subjects: 241

Group type: COMPARATOR
Intervention: Long-term oxygen therapy for 15 hours per day
Number of subjects: 241
Study: 39254489

Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel (CP)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Dostarlimab plus CP
Number of subjects: 154
Study: 39254622

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (transitioned to Mavacamten from week 16 to week 56)
Number of subjects: 112
Study: 39254740

Group type: EXPERIMENTAL
Intervention: Efsitora
Number of subjects: 928

Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 928
Study: 39254777

Group type: COMPARATOR
Intervention: Online gambling
Number of subjects: 237

Group type: COMPARATOR
Intervention: Offline gambling
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Higher perceived self-efficacy
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: No history of mood disorders
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Lower level of sensation seeking
Number of subjects: 237
Study: 39254890

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg or 50 mg once daily (with or without an initial 4-week 200-mg daily loading dose)
Number of subjects: 522
Study: 39255055

Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 597
Study: 39255440

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Savolitinib
Number of subjects: 0
Study: 39255444

Group type: EXPERIMENTAL
Intervention: B7-H3 chimeric antigen receptor (CAR) T cells at dose level 1 (DL1) 0.5 × 10^6 cells
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: B7-H3 chimeric antigen receptor (CAR) T cells
Number of subjects: 16
Study: 39255484

Group type: EXPERIMENTAL
Intervention: Smartphone-based behavioral intervention (SBI) consisting of a smart water bottle and smartphone app that alerts patients to empty their bladder and drink a personalized volume goal 1.25 hours before RT.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Smartphone-based behavioral intervention (SBI) consisting of a smart water bottle and smartphone app.
Number of subjects: 36
Study: 39255534

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days
Number of subjects: 12
Study: 39255587

Group type: EXPERIMENTAL
Intervention: mRNA-1345 100 μg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 39255991

Group type: EXPERIMENTAL
Intervention: MK-5475 32 µg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MK-5475 100 µg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MK-5475 380 µg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 39255990

Group type: EXPERIMENTAL
Intervention: BI 1291583 5 mg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: BI 1291583 2.5 mg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: BI 1291583 1 mg
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 39256281

Group type: EXPERIMENTAL
Intervention: Metallic taste (MT) experienced by patients during treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patients with metallic taste (MT)
Number of subjects: 44
Study: 39256291

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg/tramadol 50 mg (QD for 7 days)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Paracetamol 975 mg/tramadol 112.5 mg (TID for 7 days)
Number of subjects: 124
Study: 39256297

Group type: EXPERIMENTAL
Intervention: Fluorine-18 fluorodeoxyglucose (FDG) PET/CT imaging
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study: 39256350

Group type: EXPERIMENTAL
Intervention: AAV8-RLBP1 gene therapy
Number of subjects: 12
Study: 39256427

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 434
Study: 39256512

Group type: EXPERIMENTAL
Intervention: BPI-28592
Number of subjects: 1
Study: 39256658

Group type: EXPERIMENTAL
Intervention: Goal-oriented intervention for family members of patients with TBI
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 73
Study: 39256675

Group type: EXPERIMENTAL
Intervention: Anterior quadratus lumborum block (QLB3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (no block)
Number of subjects: 96
Study: 39256711

Group type: EXPERIMENTAL
Intervention: Mpox Stigma Scale (MSS)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Mpox Knowledge Scale (MKS)
Number of subjects: 330
Study: 39256781

Group type: EXPERIMENTAL
Intervention: GAmAge (newborn DNA methylation age)
Number of subjects: 831
Study: 39256835

Group type: EXPERIMENTAL
Intervention: FFA levels ≥ 580 µmol/L
Number of subjects: 10395

Group type: EXPERIMENTAL
Intervention: FFA levels < 310 µmol/L
Number of subjects: 10395
Study: 39256847

Group type: EXPERIMENTAL
Intervention: GONB + PRF
Number of subjects: 32

Group type: COMPARATOR
Intervention: GONB
Number of subjects: 32
Study: 39257031

Group type: EXPERIMENTAL
Intervention: Digital stories created by children
Number of subjects: 0
Study: 39257218

Group type: EXPERIMENTAL
Intervention: Small-group mammography video discussion (SMVD)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Video-only group
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: SMVD attendees
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: SMVD nonattendees
Number of subjects: 956
Study: 39257478

Group type: EXPERIMENTAL
Intervention: Almonds (2 oz/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isocaloric pretzel (CONTROL)
Number of subjects: 26
Study: 39257857

Group type: EXPERIMENTAL
Intervention: Personalized exercise program (PEP) intervention for fatigue
Number of subjects: 337

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 337
Study: 39257986

Group type: EXPERIMENTAL
Intervention: CASCADE approach
Number of subjects: 27
Study: 39258362

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) using a variable-loop catheter with electroanatomic mapping system
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 277
Study: 39258519

Group type: EXPERIMENTAL
Intervention: Automated peritoneal dialysis (APD)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 131
Study: 39258531

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase
Number of subjects: 4410

Group type: COMPARATOR
Intervention: Standard-dose intravenous alteplase
Number of subjects: 4410

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 4410

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering
Number of subjects: 4410
Study: 39258729

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tafamidis (started in the extension study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39258838

Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg once daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 39258961

Group type: EXPERIMENTAL
Intervention: Moderate intensity acute exercise (45-55% HRR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Higher intensity acute exercise (65-75% HRR)
Number of subjects: 60
Study: 39258976

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin administered after chemotherapy and immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 0
Study: 39259239

Group type: EXPERIMENTAL
Intervention: EPIC-HIV
Number of subjects: 13894

Group type: COMPARATOR
Intervention: No EPIC-HIV
Number of subjects: 13894

Group type: EXPERIMENTAL
Intervention: EPIC-HIV 2
Number of subjects: 13894

Group type: COMPARATOR
Intervention: EPIC-HIV vs No EPIC-HIV
Number of subjects: 13894
Study: 39259241

Group type: EXPERIMENTAL
Intervention: Soccer League (SL) intervention
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Soccer League followed by Vocational Training (SL/VT) intervention
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 1193
Study: 39259284

Group type: EXPERIMENTAL
Intervention: Reflectance Confocal Microscopy (RCM)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Dermoscopy plus clinical examination
Number of subjects: 326

Group type: COMPARATOR
Intervention: Clinical examination alone
Number of subjects: 326
Study: 39259383

Group type: EXPERIMENTAL
Intervention: Multicomponent training (MulTI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study: 39259397

Group type: EXPERIMENTAL
Intervention: Moderate-intensity free-weight resistance training to failure
Number of subjects: 41
Study: 39259541

Group type: EXPERIMENTAL
Intervention: Iloprost (1 ng/kg/min for 72 hours)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 279
Study: 39259542

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) - 1-time subcutaneous lumbar saline injection presented as placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 101
Study: 39259546

Group type: EXPERIMENTAL
Intervention: Culturally adapted, group-based lifestyle intervention (16 weeks)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Written health education materials (monthly)
Number of subjects: 549
Study: 39259550

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy for inpatients (up to 4 individual sessions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy for inpatients
Number of subjects: 200
Study: 39259563

Group type: EXPERIMENTAL
Intervention: Video visit early palliative care
Number of subjects: 1250

Group type: COMPARATOR
Intervention: In-person early palliative care
Number of subjects: 1250
Study: 39259562

Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828), oral administration, intermittent dosing schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828), oral administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Number of subjects: 0
Study: 39259927

Group type: EXPERIMENTAL
Intervention: Adjuvant Pertuzumab and Trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39259959

Group type: EXPERIMENTAL
Intervention: VR motor-cognitive training (VRMCT) - 16 one-hour training sessions delivered twice per week for 8 weeks.
Number of subjects: 293

Group type: COMPARATOR
Intervention: Usual care provided by older adult community centers (control group).
Number of subjects: 293
Study: 39259961

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 period HRU
Number of subjects: 68822

Group type: COMPARATOR
Intervention: Pre-COVID-19 period HRU
Number of subjects: 68822
Study: 39260076

Group type: EXPERIMENTAL
Intervention: suvorexant (10-20 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 39260086

Group type: EXPERIMENTAL
Intervention: Quality of social support (measured using OARS Medical Social Support score)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Quantity of social support (number of close friends and relatives)
Number of subjects: 347
Study: 39260392

Group type: COMPARATOR
Intervention: Conservative treatment (laxative regimens)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Surgical treatment (colostomy, segmental resection, hemicolectomy, subtotal colectomy)
Number of subjects: 67
Study: 39260415

Group type: EXPERIMENTAL
Intervention: Normal fetal fraction (≥10th percentile)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Low fetal fraction (<5%)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: High fetal fraction (>95%)
Number of subjects: 1041
Study: 39260540

Group type: EXPERIMENTAL
Intervention: Gefapixant (45-mg twice daily)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 39260785

Group type: EXPERIMENTAL
Intervention: Renin Angiotensin system inhibitors (RASi) therapy
Number of subjects: 2453
Study: 39260823

Group type: EXPERIMENTAL
Intervention: Psychedelic-assisted therapy using classical psychedelics (psilocybin, LSD)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Psychedelic-assisted therapy using MDMA
Number of subjects: 149
Study: 39260834

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 260

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 39260835

Group type: EXPERIMENTAL
Intervention: Omission of sentinel lymph node biopsy (SLNB)
Number of subjects: 311
Study: 39260848

Group type: EXPERIMENTAL
Intervention: Maximal tumour resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tissue biopsy
Number of subjects: 0
Study: 39260858

Group type: EXPERIMENTAL
Intervention: Regional wall motion abnormalities (RWMA) detected via transthoracic echocardiography
Number of subjects: 657
Study: 39260856

Group type: EXPERIMENTAL
Intervention: Anti-IL-17 strategy (secukinumab or ixekizumab)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Second TNF blocker
Number of subjects: 31
Study: 39260878

Group type: EXPERIMENTAL
Intervention: Laughter exercise
Number of subjects: 299

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronic acid (control group)
Number of subjects: 299
Study: 39260927

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Evogliptin 10 mg
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 39260929

Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study: 39260960

Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR valves with no THV underexpansion or eccentricity (Group 1)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR valves with underexpansion or eccentricity (Group 2)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR valves with both underexpansion and eccentricity (Group 3)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Calcium distribution assessed using CT
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with type 1 BAVs
Number of subjects: 229
Study: 39260962

Group type: EXPERIMENTAL
Intervention: BIS-guided decongestion
Number of subjects: 232
Study: 39261226

Group type: EXPERIMENTAL
Intervention: Assisted group (with machine learning predictions)
Number of subjects: 5071

Group type: COMPARATOR
Intervention: Unassisted group (without machine learning predictions)
Number of subjects: 5071
Study: 39261236

Group type: EXPERIMENTAL
Intervention: Enzalutamide with docetaxel
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pre-docetaxel ctDNA detection
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Persistence/rise of ctDNA at C2D1
Number of subjects: 157
Study: 39261265

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy for pancreatic stones (P-ESWL)
Number of subjects: 2071
Study: 39261417

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg once every 3 weeks
Number of subjects: 262
Study: 39261446

Group type: EXPERIMENTAL
Intervention: Guselkumab every 4 or 8 weeks (Q4W/Q8W)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1120
Study: 39261482

Group type: EXPERIMENTAL
Intervention: mRNA-1273 third dose
Number of subjects: 0
Study: 39261512

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Biomarkers testing immunological response and coagulopathy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Persistent symptoms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Positive serology for prior SARS-CoV-2 infection
Number of subjects: 100
Study: 39261671

Group type: COMPARATOR
Intervention: lysergic acid diethylamide (LSD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: d-amphetamine
Number of subjects: 28

Group type: COMPARATOR
Intervention: 3,4-methylenedioxymethamphetamine (MDMA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 39261786

Group type: EXPERIMENTAL
Intervention: Healthy diet combined with mindfulness cognitive therapy (educational group-based sessions on Mediterranean-type diet and mindfulness principles)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 250
Study: 39261790

Group type: EXPERIMENTAL
Intervention: Kinematic real-time feedback strategy (KRTF) with an inertial sensor
Number of subjects: 59

Group type: COMPARATOR
Intervention: Traditional methods group (G1)
Number of subjects: 59
Study: 39261815

Group type: EXPERIMENTAL
Intervention: Exercise training (group and individual) for four months, including pelvic floor muscle training (PFMT) recommended daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Group pain management course emphasizing exercise training as self-management
Number of subjects: 41
Study: 39261900

Group type: EXPERIMENTAL
Intervention: 6-monthly monitoring of serum neurofilament light chain (sNfL) in addition to usual care (group A)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Usual care with 6- or 12-monthly visits (group B)
Number of subjects: 915
Study: 39261919

Group type: EXPERIMENTAL
Intervention: Decitabine (DEC) + all-trans retinoic acid (ATRA)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 39261949

Group type: EXPERIMENTAL
Intervention: Active repetitive transmagnetic stimulation (rTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham repetitive transmagnetic stimulation (rTMS)
Number of subjects: 0
Study: 39261953

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy to address maladaptive thought patterns and behaviors around social connection
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Social prescribing intervention to connect participants with social opportunities and develop supportive social networks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 102
Study: 39261967

Group type: EXPERIMENTAL
Intervention: Mothers and Babies Virtual Group (MB-VG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Delayed receipt of the intervention (Control)
Number of subjects: 300
Study: 39262319

Group type: EXPERIMENTAL
Intervention: CI-based management (n=46)
Number of subjects: 91

Group type: COMPARATOR
Intervention: MAP-based management (n=45)
Number of subjects: 91